Zullo Investment Group Inc. Has $301,000 Stock Position in Vertex Pharmaceuticals Incorporated $VRTX

Zullo Investment Group Inc. lowered its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 15.7% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 677 shares of the pharmaceutical company’s stock after selling 126 shares during the quarter. Zullo Investment Group Inc.’s holdings in Vertex Pharmaceuticals were worth $301,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Activest Wealth Management acquired a new stake in shares of Vertex Pharmaceuticals during the 1st quarter worth about $25,000. Clal Insurance Enterprises Holdings Ltd increased its position in Vertex Pharmaceuticals by 450.0% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 45 shares in the last quarter. Flaharty Asset Management LLC bought a new position in shares of Vertex Pharmaceuticals in the first quarter worth about $32,000. American National Bank & Trust lifted its position in shares of Vertex Pharmaceuticals by 515.4% during the second quarter. American National Bank & Trust now owns 80 shares of the pharmaceutical company’s stock worth $36,000 after purchasing an additional 67 shares in the last quarter. Finally, University of Texas Texas AM Investment Management Co. acquired a new position in shares of Vertex Pharmaceuticals during the first quarter worth approximately $46,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insider Buying and Selling

In other news, Director Bruce I. Sachs bought 5,000 shares of the stock in a transaction on Wednesday, August 6th. The stock was purchased at an average price of $389.68 per share, with a total value of $1,948,400.00. Following the completion of the purchase, the director owned 45,000 shares of the company’s stock, valued at approximately $17,535,600. This trade represents a 12.50% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ VRTX opened at $407.79 on Friday. The company’s 50 day simple moving average is $393.91 and its 200 day simple moving average is $439.60. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $362.50 and a fifty-two week high of $519.88. The firm has a market capitalization of $104.55 billion, a P/E ratio of 29.15 and a beta of 0.43.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, beating the consensus estimate of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The business had revenue of $2.94 billion for the quarter, compared to analyst estimates of $2.90 billion. During the same period in the prior year, the business posted ($12.83) earnings per share. Vertex Pharmaceuticals’s revenue was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on VRTX. Canaccord Genuity Group reduced their target price on shares of Vertex Pharmaceuticals from $424.00 to $411.00 and set a “hold” rating on the stock in a research report on Wednesday, August 6th. Evercore ISI reduced their target price on shares of Vertex Pharmaceuticals from $510.00 to $475.00 and set an “outperform” rating on the stock in a research report on Thursday, September 11th. HC Wainwright reduced their target price on shares of Vertex Pharmaceuticals from $550.00 to $478.00 and set a “buy” rating on the stock in a research report on Tuesday, August 5th. Scotiabank reduced their target price on shares of Vertex Pharmaceuticals from $442.00 to $438.00 and set a “sector perform” rating on the stock in a research report on Tuesday, August 5th. Finally, UBS Group set a $553.00 target price on shares of Vertex Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have assigned a Hold rating to the company. According to data from MarketBeat, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $494.38.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.